Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes

International Journal of Cancer

Volumn 78, Issue 2, 1998, Pages 209-215

  Labarriere, Nathalie ^a   Pandolfino, Marie Christine ^b   Raingeard, Diane ^a   Le Guiner, Soizic ^a   Diez, Elisabeth ^a   Le Dréan, Eric ^a   Dreno, Brigitte ^b,c   Jotereau, Francine ^a  

^a INSTITUT DE BIOLOGIE   (France)

^b Unité de Thérapie Cellulaire et Génique   (France)

^c HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0031693028     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981005)78:2<209::AID-IJC15>3.0.CO;2-5     Document Type: Article

References (25)

1. ARUGA, A., SHU, S. and CHANG, A.E., Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol. Immunother., 41, 317-322 (1995).
2. BAKKER, A.B., SCHREURS, M.W., DE BOER, A.J., KAWAKAMI, Y., ROSENBERG, S.A., ADEMA, G.J. and FIGDOR, C.G., Melanocyte lineage-specific antigen gp-100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. exp. Med., 179, 1005-1009 (1994).
3. + tumor-infiltrating lymphocytes. J. exp. Med., 173, 647-652 (1991).
4. BRASSEUR, F. AND 29 OTHERS, Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer, 63, 375-380 (1995).
5. BURTON, R.C, and WARNER, N.L., In vitro induction of tumor-specific immunity. IV. Specific adoptive immunotherapy with cytotoxic T cells induced in vitro to plasmacytoma antigens. Cancer Immunol. Immunother., 2, 91-95, (1977).
6. DAVIS, L.G., DIBNER, M.D. and BATTEY, J.F. (eds.), Basic methods in molecular biology. Elsevier, New York (1986).
7. FONTENEAU, J.F., LE DREAN, E., LE GUINER, S., GERVOIS, N., DIEZ, E. and JOTEREAU, F., Heterogeneity of biological responses of melanoma-specific CTL. J. Immunol., 159, 2831-2839 (1997).
8. GERVOIS, N., HEUZE, F., DIEZ, E. and JOTEREAU, F., High proliferative capacity and specific anti-autologous melanoma cytotoxicity of a human T lymphocyte clone derived from tumor infiltrating lymphocytes (TIL) Hum. Immunol., 28, 112-118 (1990).
9. GUILLOUX, Y., LUCAS, S., BRICHARD, V., VAN PEL, A., DE PLAEN, E., BRASSEUR, F., LETHÉ, B., JOTEREAU, F. and BOON, T., A peptide recognized by cytolytic lymphocytes on HLA-A2 melanomas is encoded by a sequence located in an intron of the human N-acetylglucosaminyltransferase V gene. J. exp. Med., 183, 1173-1183 (1996).
10. HUM, S.S., SCHWARTZENTRUBER, D.J., ROSENBERG, S.A. and TOPALIAN, S.L., Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J. Immunother., 13, 18-30 (1993).
11. JUNG, T., SCHAUER, U., HEUSSER, C., NEUMANN, C. and RIEGER, C.J., Detection of intracellular cytokines by flow cytometry. J. Immunol., 159, 197-207 (1993).
12. KAWAKAMI, Y., ELIYAHU, S., JENNINGS, C., SAKAGUCHI, K., SOUTHWOOD, S., ROBBINS, P.F., SETTE, A., APPELLA, E. and ROSENBERG, S.A., Recognition of multiple epitopes in the human melanoma antigen gp-100 by tumor-infiltrating lymphocytes associated with in vivo tumor regression. J. Immunol., 154, 3961-3968 (1995).
13. KAWAKAMI, Y., ELIYAHU, S., SAKAGUCHI, K., ROBBINS, P.F., RIVOLTINI, L., YANNELLI, J.R., APPELLA, E. and ROSENBERG, S.A., Identification of the immunodomiant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor-infiltrating lymphocytes. J. exp. Med., 180, 347-352 (1994).
14. LABARRIERE, N., DIEZ, E., PANDOLFINO, M.C., VIRET, C., GUILLOUX, Y., LE GUINER, S., FONTENEAU, J.F., DRENO, B. and JOTEREAU, F., Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J. Immunol., 158, 1238-1245 (1997).
15. NAGOSHI, M., GOEDEGEBUURE, P.S., BURGER, U.L., SADANAGA, N., CHANG, M.P. and EBERLEIN, T.J., Successful adoptive immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-γ and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. J. Immunol., 160, 334-344 (1998).
16. NAUGHTON, G.K., EISINGER, M. and BYSTRYN, J.C., Autoantibodies to normal human melanocytes in vitiligo. J. exp. Med., 158, 246-251, (1983).
17. ROBBINS, P.F., EL-GAMIL, M., KAWAKAMI, Y. and ROSENBERG, S.A., Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res., 54, 3124-3126 (1994).
18. SALMERON, M.A., MORITA, T., SEKI, H., PLASTOUCAS, C.D. and ITOH, K., Lymphokine production by human melanoma tumor-infiltrating lymphocytes. Cancer Immunol. Immunother., 35, 211-217 (1992).
19. SONG, Y.H., CONNER, E., LI, Y., ZOROVICH, B., BALDUCCI, P. and MACLAREN, N., The role of tyrosinase in autoimmune vitiligo. Lancet, 344, 1049-1052 (1994).
20. SPAGNOLI, G.C., SCHAEFER, C., WILLIMANN, T.E., KOCHER, T., AMOROSO, A., JURETIC, A., ZUBER, M., LUSCHER, U., HARDER, F. and HEBERER, M., Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp-100 and tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int. J. Cancer, 64, 309-315 (1995).
21. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. exp. Med., 183, 1965-1971 (1996).
22. TUTTLE, T.M., MCCRADY, C.W., INGE, T.H., SALOUR, M. and BEAR, D., Gamma-interferon plays a key role in T-cell-induced tumor regression. Cancer Res., 53, 833-837 (1993).
23. VALMORI, D., LIÉNARD, D., WAANDERS, G., RIMOLDI, D., CEROTTINI, J.C. and ROMERO, P., Analysis of MAGE-3-specific cytolytic lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res., 57, 735-741, (1997).
24. VAN DEN EYNDE, B.J. and VAN DER BRUGGEN, P., T cell-defined tumor antigens. Curr. Opin. Immunol., 9, 684-693 (1997).
25. ZINKERNAGEL, R.M. and HENGARTNER, H., Antiviral immunity. Immunol. Today, 18, 258-259 (1997).